IQVIA Holdings Inc. ($IQV) Stock Forecast: Up 0.2% Today

What is IQVIA Holdings Inc.?

IQVIA Holdings Inc. (IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company's stock, IQV, had a strong bullish movement today.

Why is IQVIA Holdings Inc. going up?

IQV stock is up 0.2% on Apr 6, 2026 14:45

• IQVIA Holdings Inc. (IQV) stock price saw a significant increase following the launch of the IQVIA.ai unified agentic AI platform in collaboration with Nvidia, aimed at enhancing operational efficiency and decision-making in the life sciences industry.
• The "Buy" rating upgrade from TD Cowen and the positive reception of the platform by top pharmaceutical companies contributed to investor optimism and drove the bullish movement in IQV's stock price.
• Aberdeen Group plc's substantial increase in stake in IQVIA Holdings Inc. and the company's strong Q4 earnings performance with exceeded EPS expectations and year-over-year revenue growth further bolstered investor confidence in IQV's future prospects.

IQV Price Chart

IQV Technical Analysis

IQV News

IQVIA Holdings Inc. (IQV) stock price, news, quote and history

This Yahoo Finance page provides a comprehensive overview of IQVIA Holdings Inc. (IQV) stock, including its current price, historical data, key financial metrics, and performance against benchmarks like the S&P 500. It also details the company's business segments, analyst ratings, and allows for comparison with similar companies in the Diagnostics & Research industry. The page reflects a recent stock price of $173.26 with a slight increase and notes a "Buy" rating upgrade from TD Cowen.

https://sg.finance.yahoo.com/quote/IQV/

IQVIA (IQV) Launches IQVIA.ai Unified Agentic AI Platform with Nvidia

IQVIA Holdings Inc. (NYSE: IQV) has launched IQVIA.ai, a unified agentic AI platform developed in collaboration with Nvidia, designed for the life sciences industry. The platform aims to enhance operational efficiency and decision-making across clinical, commercial, and real-world domains by integrating IQVIA’s healthcare-grade AI and data assets with Nvidia’s advanced technology. This system, already being adopted by top pharmaceutical companies, allows for the orchestration of tasks across multiple data sources and will expand its capabilities with additional features planned for release in Q4 2026.

https://www.insidermonkey.com/blog/iqvia-iqv-launches-iqvia-ai-unified-agentic-ai-platform-with-nvidia-1732342/?amp=1

IQVIA (IQV) Launches IQVIA.ai Unified Agentic AI Platform with Nvidia

IQVIA Holdings Inc. (IQV) has launched IQVIA.ai, a new unified agentic AI platform developed in collaboration with Nvidia, specifically designed for the life sciences industry. This platform aims to enhance operational efficiency and decision-making across clinical, commercial, and real-world domains by integrating IQVIA's healthcare-grade AI and data with Nvidia's advanced technology. Many top pharmaceutical companies have already incorporated IQVIA's agents into their workflows, and the platform is set to expand its capabilities with more features planned for Q4 2026.

https://sg.finance.yahoo.com/news/iqvia-iqv-launches-iqvia-ai-183121755.html

Aberdeen Group plc Has $43.44 Million Stake in IQVIA Holdings Inc. $IQV

Aberdeen Group plc significantly increased its stake in IQVIA Holdings Inc. by 39.6% in Q4, bringing its total holding to 192,696 shares valued at $43.44 million. Other institutional investors also adjusted their positions in the medical research company. IQVIA exceeded Q4 earnings expectations with $3.42 EPS and 10.3% year-over-year revenue growth, leading analysts to maintain an average "Buy" rating with an average target price of $229.13.

https://www.marketbeat.com/instant-alerts/filing-aberdeen-group-plc-has-4344-million-stake-in-iqvia-holdings-inc-iqv-2026-04-05/

Revvity, Inc. (RVTY) stock price, news, quote and history

This Yahoo Finance page provides comprehensive financial information for Revvity, Inc. (RVTY), including its current stock price, dividend announcements, historical performance data, and key metrics. It also offers an overview of the company's health sciences solutions, its market position in diagnostics and research, and analyst insights. The page enables users to compare RVTY with similar companies in the Diagnostics & Research industry.

https://uk.finance.yahoo.com/quote/RVTY/

Trending Today

Saia Inc. ($SAIA) Stock Forecast: Up 5.3% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Up 5.6% Today

Charles Schwab Corporation (The) ($SCHW) Stock Forecast: Down 2.5% Today

VeriSign Inc. ($VRSN) Stock Forecast: Up 5.0% Today

Plug Power Inc. ($PLUG) Stock Forecast: Up 5.7% Today

IPG Photonics Corporation ($IPGP) Stock Forecast: Down 5.1% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Down 5.0% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Down 6.2% Today

Tesla Inc. ($TSLA) Stock Forecast: Down 5.1% Today

Groupon Inc. ($GRPN) Stock Forecast: Up 5.2% Today

IQVIA Holdings Inc. Price History

26.01.2026 - IQV Stock was up 5.2%

• Today's positive movement for IQVIA is linked to its acquisition of drug discovery assets from Charles River Laboratories, enhancing its early-stage research offerings and drug discovery platform.
• The rally was also supported by improved investor sentiment on biotech funding and clinical activity, positioning IQVIA as a resilient business with growth opportunities.
• Despite some concerns about fundamental aspects like revenue growth and free cash flow margin, the market is optimistic about IQVIA's strong 2025 performance projections, including revenue and EPS growth, and collaborations in AI-driven research.
• Overall, IQVIA's bullish momentum reflects investor confidence in its acquisitions, financial performance, and growth potential in healthcare and biotech sectors.

13.01.2026 - IQV Stock was up 5.0%

• Despite concerns about margin compression, IQVIA's Q4 earnings call exceeded revenue expectations, leading to a positive market reaction.
• Analysts remain optimistic about IQVIA's future performance, with recent insider buying and a "Moderate Buy" rating indicating confidence in the company's growth potential.
• The company's focus on AI integration, strategic acquisitions, and addressing macroeconomic challenges demonstrates its commitment to long-term success, driving the bullish movement in its stock price today.

05.01.2026 - IQV Stock was down 6.6%

• Despite exceeding earnings forecasts and providing optimistic guidance for 2026, IQV's stock experienced a significant drop of 9.02% in pre-market trading.
• The market's reaction to IQV's strong financial performance could be attributed to broader market dynamics and concerns about the disruptive potential of AI technologies.
• While IQV showcased robust profitability and growth, the high debt-to-equity ratio and potential liquidity challenges highlighted in the analysis might have contributed to the bearish movement in the stock.
• CEO Ari Bousbib's emphasis on AI as a positive enabler for IQVIA's business, along with strategic acquisitions and AI advancements, could be key factors to monitor for potential market recovery.

05.01.2026 - IQV Stock was down 7.6%

• Despite strong financial performance in the fourth quarter, surpassing revenue projections, IQV encountered a downward trend in the market.
• The market decline may stem from concerns surrounding the company's high debt-to-equity ratio and potential liquidity issues, possibly overshadowing the positive financial results.
• Moreover, comparisons depicting IQV as a more attractive investment choice than Idexx Laboratories could have impacted investor confidence, leading to profit-taking or a shift in investment strategies.
• Investors appear wary leading up to the upcoming earnings release, seeking clarity on margin growth and new enterprise partnerships, particularly within the Technology & Analytics Solutions sector, amid budget constraints in the biotech industry.

12.01.2026 - IQV Stock was down 8.4%

• Amid Q3 earnings strength and upbeat FY2026 guidance, IQVIA Holdings Inc. (IQV) witnessed bearish movement likely attributed to:
• Decline in share price over three years, suggesting potential misvaluation or market influences.
• A recent 26% share price plunge after financial results release, causing investor apprehension.
• Price target cuts by analysts while maintaining a "Moderate Buy" rating, reflecting market uncertainty.
• Share price drop on February 10, indicating short-term selling pressure and market volatility.

12.01.2026 - IQV Stock was down 8.3%

• Despite strong Q3 earnings and positive FY2026 guidance, IQVIA Holdings' stock dropped by 26% post-financial results, indicating investor concerns.
• The discrepancy between the company's 11% annual EPS growth and the 22% decline in share price over a three-year period suggests potential misvaluation or underlying issues impacting investor sentiment.
• The recent acquisition of a significant number of IQVIA shares by Eubel Brady & Suttman Asset Management Inc. may indicate confidence in the company's long-term prospects, though market sentiment remains cautious.
• The overall bearish trend in IQV's stock could be linked to broader challenges in the medical research sector, illustrated by negative trends in competitors such as ICON plc and Charles River Laboratories International, influencing investor sentiment industry-wide.

11.01.2026 - IQV Stock was down 5.0%

• IQVIA stock saw significant downward movement during the trading day.
• The collaboration between IQVIA and the Duke Clinical Research Institute aimed at advancing clinical research in obesity and related conditions was well-received by investors.
• Despite the upbeat response to the research partnership, the stock's decline may be linked to a decrease in ownership by Compagnie Lombard Odier SCmA, suggesting waning confidence from some institutional investors.
• The overall market outlook for IQVIA is optimistic, with analysts upholding a "Moderate Buy" consensus rating and an average price target of $239.87, indicating potential growth despite today's market performance.

04.01.2026 - IQV Stock was down 13.6%

• IQV's stock price fell by 9.18% on February 3rd, closing at $210.00.
• Investor caution and profit-taking prior to the upcoming Q4 earnings report on February 5th likely contributed to this decline.
• Despite the recent drop, analysts are optimistic about IQV's future, suggesting potential for significant growth and indicating that short-term fluctuations may be causing an overreaction in the market.
• IQV's stock underperformance relative to industry competitors and broader market indices hints at broader market sentiment and sector-specific influences impacting the bearish movement.

10.01.2026 - IQV Stock was down 5.2%

• A strategic collaboration with the Duke Clinical Research Institute to advance clinical research in obesity and related conditions is expected to have a positive impact on the company's growth and its influence on patient therapies.
• The recent reduction in stake by Compagnie Lombard Odier SCmA and Thrivent Financial for Lutherans could have contributed to a bearish movement in the stock, potentially indicating profit-taking or a shift in investor sentiment.
• Despite surpassing earnings and revenue expectations in the last quarter and offering optimistic guidance for FY 2026, concerns regarding increased interest expenses and lowered price targets by analysts may have impacted the stock's performance.
• The general market sentiment towards IQVIA is cautiously optimistic, with a consensus rating of "Moderate Buy" and an average target price of $239.87, suggesting potential for recovery ahead.

06.03.2026 - IQV Stock was up 0.2%

• IQVIA Holdings Inc. (IQV) stock price saw a significant increase following the launch of the IQVIA.ai unified agentic AI platform in collaboration with Nvidia, aimed at enhancing operational efficiency and decision-making in the life sciences industry.
• The "Buy" rating upgrade from TD Cowen and the positive reception of the platform by top pharmaceutical companies contributed to investor optimism and drove the bullish movement in IQV's stock price.
• Aberdeen Group plc's substantial increase in stake in IQVIA Holdings Inc. and the company's strong Q4 earnings performance with exceeded EPS expectations and year-over-year revenue growth further bolstered investor confidence in IQV's future prospects.

27.01.2026 - IQV Stock was up 5.2%

• Primecap Management Co. CA reduced its stake in IQVIA Holdings Inc., but other institutional investors increased their holdings, indicating varying sentiments among investors.
• The acquisition of drug discovery assets from Charles River Laboratories is seen as a strategic move to expand IQVIA's capabilities and enhance its early-stage research offerings, potentially boosting investor confidence.
• Analysts adjusting price targets for IQV post-earnings report and re-segmentation suggest a positive outlook for the company, with some considering it a strong buy despite potential competition from AI stocks.
• Broyhill Asset Management's endorsement of IQV as a top contributor to its portfolio highlights the company's strong performance and its resilience in the face of concerns over biotech funding and clinical activity, positioning it favorably in the market.

06.01.2026 - IQV Stock was up 5.4%

• Despite adjustments in price targets by various analysts, IQVIA Holdings (IQV) witnessed significant bullish movement in the market today.
• The market is responding positively to IQVIA's robust performance in Q4 2025, surpassing revenue projections and demonstrating a commitment to AI-driven solutions for future expansion.
• Analysts' concerns regarding margin pressures and sustainability of growth have been somewhat overshadowed by the company's strategic acquisitions, streamlined business operations, and optimistic 2026 forecast.
• Investors appear to find IQVIA Holdings' current valuation appealing for potential growth opportunities, despite short-term challenges highlighted by analysts.